HIGHLIGHTS
- who: Pilar García-Alfonso and colleagues from the Department of, Hospital General Universitario Gregorio Marañón, Madrid, SpainInstituto de Investigación Sanitaria (IDIS), CIBERONC, Facultad de Medicina de la Universidad de Santiago have published the article: Early Clinical Experience with Trifluridine/Tipiracil for Refractory Metastatic Colorectal Cancer: The ROS Study, in the Journal: Cancers 2021, 4514 of 20/08/2021
- what: In light of the above, this study aimed to provide further insights into the efficacy and safety of trifluridine/tipiracil for refractory mCRC in the early clinical experience in Spain, and to identify . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.